Abstract

Correlates of Protection (CoP) are biomarkers above a defined threshold that can replace clinical outcomes as primary endpoints, predicting vaccine effectiveness to support the approval of new vaccines or follow up studies. In the context of COVID-19 vaccination, CoPs can help address challenges such as demonstrating vaccine effectiveness in special populations, against emerging SARS-CoV-2 variants or determining the durability of vaccine-elicited immunity. While anti-spike IgG titres and viral neutralising capacity have been characterised as CoPs for COVID-19 vaccination, the contribution of other components of the humoral immune response to immediate and long-term protective immunity is less well characterised. This review examines the evidence supporting the use of CoPs in COVID-19 clinical vaccine trials, and how they can be used to define a protective threshold of immunity. It also highlights alternative humoral immune biomarkers, including Fc effector function, mucosal immunity, and the generation of long-lived plasma and memory B cells and discuss how these can be applied to clinical studies and the tools available to study them.

MeSH

Immunity, Humoral, Cells, Sars-Cov-2, Vaccines, Covid-19 Vaccines, Immunoglobulins, Immunity, Cellular, Biomarkers, Vaccination, Immunity, Severe Acute Respiratory Syndrome-Related Coronavirus, B-Lymphocytes, Vaccine Efficacy

Cited by

• Neutralizing Antibodies: Role in Immune Response and Viral Vector Based Gene Therapy. Int J Mol Sci, 2025